Aptevo Therapeutics, Inc.

( )
APVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.55%243.511.5%$937.22m
MRNAModerna, Inc. -2.18%142.190.0%$805.88m
REGNRegeneron Pharmaceuticals, Inc. -1.33%594.422.6%$512.04m
GILDGilead Sciences, Inc. -0.99%62.211.0%$507.75m
VRTXVertex Pharmaceuticals, Inc. -3.88%276.171.9%$501.77m
NVAXNovavax, Inc. -5.13%51.0675.7%$417.14m
ILMNIllumina, Inc. -3.06%187.433.3%$357.53m
BIIBBiogen, Inc. -5.18%202.511.8%$242.18m
SNSSSunesis Pharmaceuticals, Inc. 2.77%3.340.7%$233.48m
CRSPCRISPR Therapeutics AG -5.41%63.280.6%$169.89m
BNTXBioNTech SE -2.71%139.820.0%$166.88m
BMRNBioMarin Pharmaceutical, Inc. -2.28%83.154.2%$123.51m
EXASEXACT Sciences Corp. -6.78%41.1117.7%$99.49m
IOVAIovance Biotherapeutics, Inc. -1.35%10.980.0%$95.65m
TECHBio-Techne Corp. -2.07%346.014.5%$93.22m

Company Profile

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.